Pulmatrix Announces the Formation of the Pulmazole Clinical Advisory Board to Support Future Development
Pulmatrix, Inc. (PULM)
Last pulmatrix, inc. earnings: 8/5 09:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.pulmatrix.com
Company Research
Source: PR Newswire
LEXINGTON, Mass., July 23, 2018 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases announced today the formation of the Clinical Advisory Board (CAB) for Pulmazole (PUR1900) – an inhaled iSPERSE™ formulation of the anti-fungal drug itraconazole for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma. The members of the CAB are world-renowned experts in the fields of both ABPA and asthma and will work closely with Pulmatrix to design and implement future clinical studies of Pulmazole. "I am very encouraged by the Phase 1 results demonstrating that it is both feasible to administer itraconazole by inhalation and further that high levels of the drug may be achieved within the airways," stated Dr. David Denning, Professor of Infectious Diseases in Global Health and the Director of the National Aspergillosis Cent
Show less
Read more
Impact Snapshot
Event Time:
PULM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PULM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PULM alerts
High impacting Pulmatrix, Inc. news events
Weekly update
A roundup of the hottest topics
PULM
News
- Pulmatrix, Inc. (NASDAQ: PULM) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- 14-alpha Demethylase Inhibitors Drug Landscape Research Report 2024: Comprehensive Insights on 12+ Companies and 12+ Pipeline Drugs [Yahoo! Finance]Yahoo! Finance
- Pulmatrix, Inc. (NASDAQ: PULM) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Pulmatrix, Inc. (NASDAQ: PULM) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
PULM
Sec Filings
- 3/28/24 - Form 424B3
- 3/28/24 - Form 10-K
- 3/28/24 - Form 8-K
- PULM's page on the SEC website